These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18533934

  • 1. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
    Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M.
    Pediatr Int; 2008 Jun; 50(3):269-75. PubMed ID: 18533934
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
    Iwasaki T, Nonoda Y, Ishii M.
    Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonate use in children with cerebral palsy.
    Hurley T, Zareen Z, Stewart P, McDonnell C, McDonald D, Molloy E.
    Cochrane Database Syst Rev; 2021 Jul 05; 7(7):CD012756. PubMed ID: 34224134
    [Abstract] [Full Text] [Related]

  • 4. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A, Higashi M, Namisato M, Nishio M, Ando K, Yamada H.
    Lepr Rev; 2006 Jun 05; 77(2):147-53. PubMed ID: 16895071
    [Abstract] [Full Text] [Related]

  • 5. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
    Cohran V, Cassedy A, Hawkins A, Bean J, Heubi J.
    J Pediatr Rehabil Med; 2013 Jun 05; 6(2):85-93. PubMed ID: 23803341
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    Intern Med; 2008 Jun 05; 47(8):717-23. PubMed ID: 18421187
    [Abstract] [Full Text] [Related]

  • 7. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep 05; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 8. [Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].
    Ohbayashi H.
    Nihon Rinsho; 2009 Jan 05; 67(1):206-12. PubMed ID: 19177774
    [Abstract] [Full Text] [Related]

  • 9. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep 05; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 10. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Kitagawa Y, Koh E, Namiki M.
    Prostate Cancer Prostatic Dis; 2011 Sep 05; 14(3):238-42. PubMed ID: 21423267
    [Abstract] [Full Text] [Related]

  • 11. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    J Bone Miner Metab; 2009 Sep 05; 27(2):168-74. PubMed ID: 19183836
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K.
    J Bone Miner Metab; 2006 Sep 05; 24(2):105-13. PubMed ID: 16502116
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1239-45. PubMed ID: 23265571
    [Abstract] [Full Text] [Related]

  • 14. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
    Iba K, Takada J, Hatakeyama N, Ozasa Y, Wada T, Yamashita T.
    J Orthop Sci; 2008 Sep 01; 13(5):438-41. PubMed ID: 18843458
    [Abstract] [Full Text] [Related]

  • 15. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 01; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.
    Takakuwa M, Otsuka K, Konishi M, Itabashi K.
    J Int Med Res; 2009 Apr 01; 37(6):1972-81. PubMed ID: 20146897
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 01; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 18. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A.
    Int J Clin Pract; 2008 Jun 01; 62(6):919-24. PubMed ID: 18422590
    [Abstract] [Full Text] [Related]

  • 19. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Jun 01; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb 01; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.